‘Ajovy’ is also following the steps of ‘Emgality’ and seeks health insurance benefits in Korea.

According to industry sources, Teva-Handok Pharma applied for the reimbursement of its calcitonin gene-related peptide (CGRP) targeting migraine drug Ajovy (fremanezumab). The company quickly applied for reimbursement since launching the drug without reimbursement in October last year.

With slow progress being made for the reimbursement of Lilly's Emgality (galcanezumab),’ which applied for reimbursement in April last year, whether the addition of Ajovy to the game will create a synergistic effect remains a point of focus.

Both drugs are currently prescribed without reimbu